PitchBook/NVCA tallies show Texas startups raised $5.8B in Q1 versus Massachusetts’ $5.3B, driven by several massive defense and robotics rounds in Austin. The reversal highlights how a few big deals can flip statewide VC rankings quickly.

Swedish AI startup Lovable opened a Downtown Crossing office at One Lincoln and plans to hire dozens for sales and customer roles.

Mass General Brigham researchers found plasma pTau217 rises years before amyloid shows on PET scans, offering a cheaper path to earlier Alzheimer's detection and trial recruitment.

Harbinger Health raised $100M to push a multi-cancer blood test toward launch. The Cambridge company says the tests will screen for about 12 cancers as it scales lab operations.

Seaport Therapeutics filed to go public, aiming to raise roughly $100M to advance its Glyph neuropsychiatry pipeline.

Wasabi has closed its acquisition of Seagate’s Lyve Cloud, folding the S3‑compatible platform into its hot‑cloud stack and accelerating its push into AI‑ready storage.

Life Biosciences closed an $80M Series D to fund a first-in-human ER-100 trial and expand its partial epigenetic reprogramming pipeline.

A federal judge found a customs officer wrongly revoked a Harvard researcher's visa after frog-embryo samples were found at Logan Airport, a decision with wide implications.

Gilead will acquire Munich-based Tubulis for $3.15B upfront, with up to $1.85B in milestones; the deal highlights Tubulis’ small Cambridge Innovation Center office.

HubSpot is rebranding its flagship Inbound conference to Unbound as the company pivots to AI after a steep stock slide. The change is part of a broader product and pricing shift.

U.S. News' 2026 research rankings left Massachusetts without a Tier 1 medical school; Tufts and UMass Chan were the state's highest‑ranked programs in Tier 2.

Korsana will take Cyclerion’s Nasdaq listing through an all‑stock reverse merger backed by about $380M, giving the startup cash into 2029 and a faster route to 2027 readouts. The combined company will trade as KRSA.

Eli Lilly will buy Boston‑based Centessa for about $6.3B, adding an orexin agonist program led by cleminorexton. The deal pays $38 per ADS up front and could reach $47 with milestones.